• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Nistala Kiran

    1/26/24 11:27:15 AM ET
    $JATT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $JATT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Nistala Kiran

    (Last) (First) (Middle)
    C/O ZURA BIO LIMITED
    1489 W. WARM SPRINGS RD. #110

    (Street)
    HENDERSON NV 89014

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Zura Bio Ltd [ ZURA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    See Remarks
    3. Date of Earliest Transaction (Month/Day/Year)
    01/24/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock options $3.98 01/24/2024 A 350,000(1) (1) 01/24/2034 Class A Ordinary Shares 350,000 $0 350,000 D
    Explanation of Responses:
    1. Consists of options to purchase 350,000 Class A Ordinary Shares. The vesting for 350,000 shares began on November 27, 2023 and would vest over a period of four years, with 1/4 to be vested on 11/27/2024, and thereafter 1/48 on a monthly basis.
    Remarks:
    Executive Vice President
    /s/ Kiran Nistala 01/26/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $JATT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JATT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $JATT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

      SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

      2/14/24 4:39:38 PM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

      SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

      2/14/24 9:02:53 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

      SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

      2/14/24 6:05:55 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JATT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp

      Zura Bio Limited to trade on Nasdaq as a clinical-stage biotechnology company focused on immunology Business combination results in approximately $65 million in gross cash proceeds to support research and development initiatives and potential future acquisitions Combined company to trade on Nasdaq under ticker "ZURA" commencing March 21, 2023 Zura Bio Limited ("Zura"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the closing of its business combination with JATT Acquisition Corp, a special purpose acquisition company (NYSE:JATT) ("JATT"), on March 20, 2023. The business combination was

      3/21/23 6:13:00 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JATT Acquisition Corp Shareholders Approve Proposed Business Combination with Zura Bio Limited

      JATT Acquisition Corp (NYSE:JATT) ("JATT"), a publicly traded special purpose acquisition company, today announced that its shareholders voted to approve its proposed business combination with Zura Bio Limited ("Zura"), a clinical-stage biotechnology company. At the extraordinary general meeting of JATT's shareholders, a total of 4,907,863 ordinary shares, or 95.5% of JATT's issued and outstanding ordinary shares as of February 16, 2023, the record date of the extraordinary general meeting, were present either in person or represented by proxy. Holders of 4,903,764 ordinary shares, or 99.9% of the votes cast at the meeting, voted in favor the business combination. At the closing of the bu

      3/16/23 4:17:00 PM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JATT Acquisition Corp Announces Planned Transfer of Listing to NASDAQ in Connection with its Proposed Business Combination with Zura Bio Limited

      JATT Acquisition Corp (NYSE:JATT, JATT.WS and JATT.U))) (the "Company"), a publicly-traded special purpose acquisition company, today announced that it will voluntarily transfer the listing of its Class A ordinary shares, public warrants and units from the New York Stock Exchange ("NYSE") to the Nasdaq Stock Market LLC ("Nasdaq") in connection with, and upon the closing of, the previously announced business combination (the "Business Combination") with Zura Bio Limited, a limited company incorporated under the laws of England and Wales ("Zura"). The Company expects that listing and trading of its listed securities on the NYSE will end at market close on March 20, 2023. The Class A ordinary

      3/13/23 9:28:00 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JATT
    SEC Filings

    See more
    • JATT Acquisition Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Zura Bio Ltd (0001855644) (Filer)

      2/2/24 6:02:07 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JATT Acquisition Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Zura Bio Ltd (0001855644) (Filer)

      1/11/24 5:25:15 PM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JATT Acquisition Corp filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Zura Bio Ltd (0001855644) (Filer)

      1/8/24 6:03:32 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JATT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Lisicki Robert

      4 - Zura Bio Ltd (0001855644) (Issuer)

      1/26/24 11:33:20 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Ploos Van Amstel Arnout

      4 - Zura Bio Ltd (0001855644) (Issuer)

      1/26/24 11:32:02 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Thiara Parvinder

      4 - Zura Bio Ltd (0001855644) (Issuer)

      1/26/24 11:30:45 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care